UNITED STATES: AIDS at 25 CDC Daily UpdateImportant note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
Click here to return to CDC Daily Update main menu
DonateNow
Print this article

UNITED STATES: AIDS at 25

Los Angeles Times (06.05.06) - Tuesday, June 06, 2006
Thomas H. Maugh II, Jia-Rui Chong


Twenty-five years after the onset of the HIV/AIDS epidemic, both an AIDS vaccine and a cure are still remote possibilities. At least 96 US-sponsored vaccine trials are underway, but experts agree that none is likely to yield a useful product, though they may point to better candidates. Even potential vaginal microbicide products remain years away. What drugs are entering the marketplace are the result of old research.

"The low-hanging fruits have all been picked. and we still face huge challenges," said Dr. David Ho of the Aaron Diamond AIDS Research Center in New York. "This is not because of a lack of effort or because of a lack of money. It's just a fundamental problem posed by HIV."

In the United States since 1981, more than half a million people have died from HIV/AIDS complications. According to CDC, an estimated 15,000 will die from them this year. More than 1 million people in the United States have HIV/AIDS, and 40,000 contract it each year.

African Americans, some 13 percent of the population, account for half of new US infections and one-third of deaths. Black males are seven times as likely as white males to have HIV; black females are 20 times as likely to be infected as white females.

Worldwide, at least 25 million people have died from AIDS, and 2.8 million will die this year, according to the World Health Organization. An estimated 38.6 million people have HIV/AIDS, and an additional 4.1 million are infected each year in what Dr. Kevin Fenton, head of AIDS programs at CDC, called "one of the deadliest epidemics in human history."

"We are the last generation to know what life in a world without AIDS was really like," said Dr. James Curran, who was among the first at CDC to study the disease, and who is currently dean of Emory University's Rollins School of Public Health.
060606
AD060978


Copyright © 2006 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .